Synonyms: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37],

Sequence: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(γ-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

M.W: C172H265N43O51

M.F.: 3751.2

Purity: 95% by HPLC

Counter ion: Trifluoacetate

Format: Lyophilized powder

Description: Liraglutide is the first GLP-1 analog that is under development for the obesity indication. Liraglutide dose dependently lowers body weight by reducing energy intake via an overall appetite reduction. Phase 3 clinical trials have been completed, and applications to market liraglutide as a drug for treatment of obesity have been filed in the US and EU.

Drug Bank ID: http://www.drugbank.ca/drugs/DB06655

Usage: For Scientific Research Use Only, Not for Human Use.

Reference:

Ann Pharmacother. 2009 Sep; 43(9):1433-44.

Diabetes Metab Syndr Obes. 2010 Jul 14; 3:215-26.

Am J Manag Care. 2011 Mar; 17(2 Suppl):S59-70.

Clin Ther. 2011 Jul; 33(7):793-811.

Cardiovasc Diabetol. 2012 Sep 14; 11:107.

Endocr J. 2012; 59(10):889-94.

Am J Ther. 2013 Mar-Apr; 20(2):178-88.